Market news

Cybin (NasdaqGM:HELP), which is rebranding as Helus Pharma, has just wrapped up a pivotal shareholder meeting approving a legal name change and confirming its full director slate for the coming year. For investors tracking Cybin, the legal rebrand to Helus Pharma comes after a sharp run in the share price over recent months. The 90 day share price return is 116.28% and the 1 year total shareholder return is 115.56%. In contrast, the 3 year total shareholder return is down 37.40% and the 5...

Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting hol

Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv

Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global Investment Conference. The company, referred to in the presentation as Helus Pharma, is developing se

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline. Speaki

Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major depressive disorder, and the appointment of Michael Halstead as CEO. Cybin’s share price has moved sharply in recent months, with a 1 month share price return of 83.53% and a 90 day share price return of 215.69%. The 1 year total shareholder return of 87.72% contrasts with a weaker 5 year total...

Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along with updates around peers’ late stage programs and regulatory tone, is helping shape how analysts frame this higher fair value range for Cybin. Read on to see how these shifting assumptions and new data points can help you track the evolving narrative around the stock. Stay updated as the Fair...

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treatment for major depressive disorder. Speaking at a Canaccord Genuity event, Halstead, w

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 - - Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD - - Continued enrol

GlobeNewswire Press Release.

Cybin’s updated analyst model features a reduced fair value estimate, with the price target moving from US$49.46 to US$37.57, a cut of about 24% in the projected equity value per share. This change sits against a backdrop of mixed sector commentary on psychedelic drug developers, where optimism around potential pharma deals and regulatory clarity is balanced by caution on valuation resets and deal outcomes. As you read on, you will see how these shifting assumptions feed into the evolving...

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.

Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently completed an underwritten public offering raising about US$50,000,000 to fund development. This combination of late-stage clinical progress and fresh capital support highlights how Cybin is positioning HLP003 as a potential clinic-based mental health therapy within its broader psychedelic treatment...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list. TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating […]

Initiating Helus Pharma with a speculative Buy ahead of Q4 2026 Phase 3 APPROACH readout; undervalued HLP003 MDD asset offers upside. Click for more on HELP stock.

An in-depth look at the leading psychedelic stocks in the U.S. stock market this year. Here's what you need to know.